Tech Company Financing Transactions
A-Alpha Bio Funding Round
A-Alpha Bio closed a $22.4 million Series A investment round on 7/25/2023. Investors included Breakout Ventures, Madrona Venture Group and Perceptive Advisors.
Transaction Overview
Company Name
Announced On
7/25/2023
Transaction Type
Venture Equity
Amount
$22,400,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds for further development of its AlphaSeq and AlphaBind platforms and accelerate their oncology-focused internal pipeline.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
4000 Mason Rd. Fluke Hall 304
Seattle, WA 98195
USA
Seattle, WA 98195
USA
Phone
Website
Email Address
Overview
Accelerating drug development with synthetic biology and next-generation sequencing. We are a team of synthetic biologists and next-generation sequencing experts focused on disrupting the way that pharmaceutical companies discover, optimize, and characterize drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Younger
Chief Technical Officer
Randolph Lopez
Vice President
Ryan Emerson
Browse more venture capital transactions:
Prev: 7/25/2023: Immediate venture capital transaction
Next: 7/25/2023: Kandle venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs